Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01AB01
|
| gptkbp:brand |
gptkb:Busulfex
gptkb:Myleran |
| gptkbp:CASNumber |
55-98-1
|
| gptkbp:chemicalFormula |
C6H14O6S2
|
| gptkbp:discoveredBy |
1950s
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:hasSMILES |
O=S(=O)(OCCOCCOCCOS(=O)(=O)C)C
|
| https://www.w3.org/2000/01/rdf-schema#label |
busulfan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:meltingPoint |
103-105 °C
|
| gptkbp:MeSH_ID |
gptkb:D002052
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
246.3 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL608
gptkb:DB01008 2476 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
pulmonary fibrosis
seizures myelosuppression hyperpigmentation |
| gptkbp:UNII |
G1LN9045DK
|
| gptkbp:usedFor |
conditioning regimen before bone marrow transplantation
treatment of chronic myelogenous leukemia |
| gptkbp:bfsParent |
gptkb:multidrug_resistance-associated_protein_1
|
| gptkbp:bfsLayer |
6
|